A meta-analysis of first-line immunotherapy combinations for advanced NSCLC demonstrated that the addition of bevacizumab to chemotherapy plus ICI does not provide significant survival benefits over chemotherapy plus ICI alone for PD-L1-negative patients, while also increasing toxicity and treatment complexity (22). The gene discussed is CD274; the disease is non-small cell lung carcinoma.